Author | F. Anthony Greco, MD


The Impact of Molecular Testing on Treatment of Cancer of Unknown Primary Origin

August 15, 2013

The preponderance of data support the accuracy of molecular assay diagnoses in about 80% to 90% of patients with known advanced primary cancers and in patients with cancer of unknown primary origin.

Commentary (Thomas/Greco): Myalgias and Arthralgias Associated With Paclitaxel

February 01, 2003

Despite nearly a decade of paclitaxel’scommercial availability,the best strategy formanaging several paclitaxel-relatedtoxicities including myalgia/arthralgiaremains to be elucidated. Mostavailable data in the treatment of myalgia/arthralgia have been anecdotal,reported in the form of case studiesor within the toxicity results of publishedpaclitaxel-containing clinicaltrials. Garrison et al have provided awell-written review summarizingwhat is currently known about theincidence and management of thisquality-of-life–impacting toxicity.

Current Role of Irinotecan in the Treatment of Non-Small-Cell Lung Cancer

September 01, 2002

Dr. Kelly has provided a complete, well-written review of the current status and evolving role of irinotecan (CPT-11, Camptosar) as a cytotoxic agent for patients with non-small-cell lung cancer (NSCLC). Her review clearly demonstrates the value of irinotecan in this patient population and further supports the continued development of this agent in concert with other chemotherapeutic agents, biologically targeted agents, surgery, and/or radiotherapy.

Commentary (Greco)-Limited Small-Cell Lung Cancer: A Potentially Curable Disease

October 01, 2000

Patients with limited-stage small-cell carcinoma of the lung are treated with combined-modality therapy with the intent to cure. Standard therapy consists of platinum-based combination chemotherapy, thoracic irradiation, and